{"name":"Immunic AG","slug":"immunic-ag","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"IMU-838 tablets","genericName":"IMU-838 tablets","slug":"imu-838-tablets","indication":"Ulcerative colitis","status":"phase_3"},{"name":"Placebo matching IMU-838 tablets","genericName":"Placebo matching IMU-838 tablets","slug":"placebo-matching-imu-838-tablets","indication":"Ulcerative colitis","status":"phase_3"}]}],"pipeline":[{"name":"IMU-838 tablets","genericName":"IMU-838 tablets","slug":"imu-838-tablets","phase":"phase_3","mechanism":"IMU-838 is a selective immunomodulator that inhibits dihydroorotate dehydrogenase (DHODH) to reduce proliferation of activated lymphocytes while preserving regulatory T cells.","indications":["Ulcerative colitis","Crohn's disease","Primary biliary cholangitis (PBC)"],"catalyst":""},{"name":"Placebo matching IMU-838 tablets","genericName":"Placebo matching IMU-838 tablets","slug":"placebo-matching-imu-838-tablets","phase":"phase_3","mechanism":"IMU-838 is a selective immunomodulator that inhibits intracellular signaling pathways to reduce pathogenic immune responses.","indications":["Ulcerative colitis","Crohn's disease","Relapsing-remitting multiple sclerosis"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-02-13","type":"pipeline","source":"boerse.de","summary":"EQS-News: Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into Commercial-Stage Company - boerse.de - boerse.de","headline":"EQS-News: Immunic Announces Oversubscribed Private Placement of up to USD 400 Million to Accelerate Transformation into ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxQMDlsRFUzUm1sUVBjdkJCalR3TWdOVnZWV1MwcG5pMWlGelpHNjdRLWpoNUdnbFBMMGJvaC1jQzhVV2c1ZXYxWlFrQUFmcE82NXMxbnBSeElRNFViZVM4QXotVVU2ZWRLMmFzLXdYRHdSeXV1NmlRc0dCdGg3SG0zbVd6eU9tWWRFM3RjNVJtQnlIYkR4Mkp1elA0ODlDWm5VTlk1Ng?oc=5","date":"2026-02-02","type":"pipeline","source":"The Pharma Letter","summary":"Resolve M Therapeutics exits stealth with immune platform - The Pharma Letter","headline":"Resolve M Therapeutics exits stealth with immune platform","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE94RzZZRGdJOVJ5MktMQ1VwU2cteW5xZV9LOWIxUzRvUlZLb1RwM2Z0WV82UVBBX05pUi1EWGxybFpxTUYtU0xuNElZTDloc25aYUN0cmNJbjA2UUdOWHdn?oc=5","date":"2026-01-13","type":"trial","source":"Nature","summary":"Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial - Nature","headline":"Linavonkibart and pembrolizumab in immune checkpoint blockade-resistant advanced solid tumors: a phase 1 trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgJBVV95cUxQck9IdmdhSWsza0ZVT0ZaeDVEWHROX2poanB4UEk0aGpiUDFhSzUwTHhoVm1leHV5SnBXejdsT2JCZ2dQdnpKYnJZXy14cl94ZmR1SDRERURUMHlrbERRdjVNd2t1MWg4QjRpUWV0Y1pVd0poN3hnQzFoM2NFX0tVbGEzSkE3RXdXUUYxck5OTXZFdUZ3UzdEX1hSQkhVMk0xYnhMT2lwenBKT2dtSWpscDIyRjFiek1sbWRVWW1vUGtzS2xreHJtWWlmSUt4ZnAyVG1XWWV3c0xzLUxtVXJ0ZWN1cFdMVWtkZ0xlbWJIR25yYVc0V2NXVmFtR2ROMmRlTVktRUhtcm8xZWM2VHlhMHZzR0VqZmVfNHNxeS1GX2pNaWhXbDh3dEpZNjNVVXVlY21hQzYwdHdTbEdtV3c?oc=5","date":"2025-12-17","type":"pipeline","source":"PR Newswire UK","summary":"Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Novel Therapy Adoption Landscape | DelveInsight - PR Newswire UK","headline":"Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and Nove","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPSmdLQ2g3SndGaWhzbDZlRVFVU05SUW1seXhRQ0NpTVZ0VGpvQy0yWnlBSFpGa0xZbWxMMk9JcjdXWkNiZ1VVWHRobHNmUXZuZ01xNDBvRFJlNm9nOGhXTVFyRGFDX0pRSGRrUXhkQW1EZHp3UmtLSEpkd0hLMlZxY18zS1FwMWZzWi1pcg?oc=5","date":"2025-10-09","type":"pipeline","source":"Global Growth Insights","summary":"Top 13 Immune Checkpoint Inhibitors Companies in 2025 - Global Growth Insights","headline":"Top 13 Immune Checkpoint Inhibitors Companies in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQbWEyejA2UTd1Q0FVWFM1VG1BZnRCMzdSVy1BcnFaWllMT194WWdHTEpGSFVWR3pCSlcxaTFnVUJSV2tmRi0zVXpoN0RvYXZSZW0zSkRJaEJtandxWVF2WlhUdGRZb2t3ejk5M2lPajVMWWpicFNodVZYMnJ6SG0xWnpyNUtEeTFyckhqTW1HNnF2eGk2ckV5bEJ1VENPSnEyUVZodGg0VmtiU0NwcmpzVk1MVzhJNlI2YlFNRFJtbXNsbXo1R3pF?oc=5","date":"2025-10-07","type":"pipeline","source":"Reuters","summary":"Immune system breakthrough wins Nobel medicine prize for US, Japan scientists - Reuters","headline":"Immune system breakthrough wins Nobel medicine prize for US, Japan scientists","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi3AFBVV95cUxNdG9FYUFjUVpGNWRwNFc5VjJTNG9BdTU5aUdOSzJ5WUxaQkJMRks3eGxPTktTcGxHQUdRVmd0cllIUV9aWmtzUlZHVUN2dV8xajF3V0FkVFgteERsN2JudEl2V3dKX3V0b1gtVmxnX05HNEVnTDY3b28tQ3V0ZGg2VmItbEQtX21xZjVlaExsaUlPa3RwMkpZSXNIbi1QY09GOWR0SHRYMF90US0xNl9pVGw0bV9FdnhqMS1wWWJreTJoRThoT2JUMkstVVY2ZWlzd2hnYUUwOXY3ZXg5?oc=5","date":"2025-09-15","type":"deal","source":"Reuters","summary":"Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics - Reuters","headline":"Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQTUhmcVZoWGhzbHpEYzdnRlFMaTU3ZFAzM0pqZ1llZTdzak96SVJMXzJpa3VJVUswLVV0RTIwS1hZNHFQZHI0Y19DMG1SdTBtSENSZVh1anRHcWQ5R3NQRW93SUxKbGVlTzdDdFM4MjI1TFNtWHBVanpkQ1c1S0pEeFpHVlU5RkR3SHNFWFB2aw?oc=5","date":"2025-05-14","type":"pipeline","source":"Grand View Research","summary":"Top 20 Multiple Sclerosis Drugs Market Analysis and Segment Forecasts To 2030 - Grand View Research","headline":"Top 20 Multiple Sclerosis Drugs Market Analysis and Segment Forecasts To 2030","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9ZM0Y5Z25zX3l5U3ZSQzlyZUVHbFRKam1jYXRFYUM0U0RKWlFZb2ZNb181dmFHSXNESUZpNTJjRjMtOVpMdUtJTmhjNmNRMW5Kdl96R0xCRmI1eTF3dXdv?oc=5","date":"2025-05-06","type":"pipeline","source":"Nature","summary":"Immune–epithelial–stromal networks define the cellular ecosystem of the small intestine in celiac disease - Nature","headline":"Immune–epithelial–stromal networks define the cellular ecosystem of the small intestine in celiac disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQaVBqZjZUTDdKWkFjbDQ5UTRVaU9WejVJRDJ2X1JqQW5sQlRxRW1OUG82and1LXNaWEIta0U2akg2UU80V2l4RzY1OWF4bHBnTk0zQmZmc3pPeDBlbjVZalpwbTR2MmZPN0IwajI3OS1ndlZnWXZDbkF3OEd5dFpRa3F0aERMdkRGUGkxM0ZSQQ?oc=5","date":"2025-04-23","type":"pipeline","source":"BioPharma Dive","summary":"Roche looks to a Flagship startup in search of new immune drugs - BioPharma Dive","headline":"Roche looks to a Flagship startup in search of new immune drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxOX2dNS05WY0lZb0M1TW5pT2o5VDJhb3U1SWpxTXZVb21ZdW9XSEtOdEdNdkNoUGNBQlBhMzk1Qk1vMlYtX0V6alBKUEQzRllzZWdyenJqSVNpQXpOS0lGRWxFcWtaRERmS2VmZ0ZtM0JfS185WHZMdUdyNEZiZTAxZGlBWHVsZDNlbnd1anNCdFU0bGRLa0NpNDFsNGllRlhoR2paVkprU3J1T1F3?oc=5","date":"2024-12-18","type":"pipeline","source":"Investing.com","summary":"Immunic CEO Daniel Vitt secures new employment terms - Investing.com","headline":"Immunic CEO Daniel Vitt secures new employment terms","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPTzBrc2t3RG9tSy1xWWZhVGlzd1dvVVdFNTRlY1RWb25CLTRkQ2p1TGVyRUREM3VSY3lxZ2tWVnFlaUpqeU5Zel8zUy1hVk1Hb0RPbUdHZ3RxWlFVQVpocXkwc0o4eUhuQ3p6enNENHJWZjhnc3oxVUtRMERZRDZEcUhobDlfNFJaaml2SHVUb2ZfTUFZNE9oR2xxcVM?oc=5","date":"2024-07-09","type":"pipeline","source":"Contract Pharma","summary":"Immunic Welcomes Jason Tardio as COO and President - Contract Pharma","headline":"Immunic Welcomes Jason Tardio as COO and President","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}